drugset / Trial / NCT01005069
Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to investigate clinical efficacy and safety of DLBS 32 in the management of subjects with type-II-diabetes mellitus and to determine the minimal effective dose of DLBS 32 for subjects with type-II-diabetes mellitus.
Timeline
- Start
- 2009-10
- Primary completion
- 2010-07
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DLBS-32 | Unknown | 50 mg | — |
| Subject | DLBS-32 | Unknown | 100 mg | — |
| Subject | DLBS-32 | Unknown | 200 mg | — |
| Subject | DLBS-32 | Unknown | 300 mg | — |